Literature DB >> 9347202

The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.

M A Lewis1, L A Heinemann, W O Spitzer, K D MacRae, R Bruppacher.   

Abstract

The objective of this study was to assess the risk of myocardial infarction (MI) associated with the use of new and old combination oral contraceptives (OC). A matched case-control study in 16 centers in Germany, the United Kingdom, France, Austria, and Switzerland explored the association of current use of combination OC with the occurrence of MI. Our subjects were 182 women aged 16-44 years with MI; the controls were 635 women without MI (at least one hospital control and one community control per case) matched for 5-year age group and region. The main outcome measures were odds ratios comparing current use of a specific group of OC against current use of other groups or against no current use. The adjusted overall odds ratio (OR; 95% confidence intervals) for MI for second generation OC versus no current use was 2.35 (1.42 to 3.89) and 0.82 (0.29 to 2.31) for third generation OC (low dose ethinyl estradiol, gestodene, and desogestrel). A direct comparison of third generation users with second generation users yielded an OR of 0.28 (0.09 to 0.86). In subgroup analyses, the odds ratio for the UK alone was 1.25 (0.36 to 4.29), while for continental Europe it was 0.10 (0.02 to 0.48). For hospital controls, the risk estimated was 0.98 (0.22 to 4.44), and 0.18 (0.04 to 0.65) for community controls. The independent risk of MI among current smokers adjusted for OC use was 7.21 (4.58 to 11.36). Among users of third generation OC, the OR for current smokers was 3.75 (0.65 to 21.74) and among users of second generation it was 9.50 (2.93 to 30.96). A comparison of OC use in the UK for the time before and after regulatory action was taken in October 1995 shows that the likelihood of a control (last control accrued June 1996) being treated with second generation OC is seven times higher after 1 November 1995 than it was before. Third generation OC are the first to be associated with no excess risk of MI. A significantly lower risk of MI is found when comparing use of third generation OC with use of second generation OC. There seems to be an impressive amelioration of risk among smokers using newer OC. An impact of regulatory action in the UK was found in the OC use spectrum of controls.

Entities:  

Keywords:  Austria; Behavior; Case Control Studies; Contraception; Contraceptive Agents, Female--pharmacodynamics; Contraceptive Agents, Progestin--pharmacodynamics; Contraceptive Agents--pharmacodynamics; Contraceptive Methods--side effects; Desogestrel--pharmacodynamics; Developed Countries; Diseases; Europe; Evaluation; Family Planning; France; Germany; Gestodene--pharmacodynamics; Heart Diseases; Levonorgestrel--pharmacodynamics; Mediterranean Countries; Myocardial Infarction; Northern Europe; Oral Contraceptives, Combined--side effects; Oral Contraceptives--side effects; Research Methodology; Research Report; Risk Assessment; Smoking; Studies; Switzerland; United Kingdom; Western Europe

Mesh:

Substances:

Year:  1997        PMID: 9347202     DOI: 10.1016/s0010-7824(97)00118-2

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  17 in total

1.  The third generation oral contraceptive controversy. The evidence shows they are less safe than second generation pills.

Authors:  P A O'Brien
Journal:  BMJ       Date:  1999-09-25

Review 2.  Benefits and risks of third-generation oral contraceptives.

Authors:  E S Leblanc; A Laws
Journal:  J Gen Intern Med       Date:  1999-10       Impact factor: 5.128

3.  Study confirms tendency towards lower risk of myocardial infarction with second generation oral contraceptives in UK.

Authors:  P O'Brien
Journal:  BMJ       Date:  1999-10-30

Review 4.  Cardiovascular events associated with different combined oral contraceptives: a review of current data.

Authors:  P Hannaford
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

5.  Combined oral contraceptives, smoking, and cardiovascular risk.

Authors:  T M Farley; O Meirik; C L Chang; N R Poulter
Journal:  J Epidemiol Community Health       Date:  1998-12       Impact factor: 3.710

6.  Oral contraceptives and myocardial infarction: results of the MICA case-control study.

Authors:  N Dunn; M Thorogood; B Faragher; L de Caestecker; T M MacDonald; C McCollum; S Thomas; R Mann
Journal:  BMJ       Date:  1999-06-12

7.  Risk of myocardial infarction in young female smokers.

Authors:  N R Dunn; B Faragher; M Thorogood; L de Caestecker; T M MacDonald; C McCollum; S Thomas; R Mann
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

Review 8.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 9.  Risk of cardiovascular events with hormonal contraception: insights from the Danish cohort study.

Authors:  Omosalewa O Lalude
Journal:  Curr Cardiol Rep       Date:  2013-07       Impact factor: 2.931

Review 10.  Hormonal contraception in adolescents: special considerations.

Authors:  Rollyn M Ornstein; Martin M Fisher
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.